Multitasking Asynchronous Collaborative Nanosystem for Diabetic Wound Healing Based on Hypoglycemic, Antimicrobial, and Angiogenesis‐Promoting Effects
Source abstract
Abstract
Abstract A diabetic foot ulcer (DFU) is a common and serious complication of diabetes. This complication can result in amputation and death because of the several challenges associated with wound healing that can be attributed to the complex wound microenvironment, including biofilm infection, hyperglycemia, and diabetic angiopathy. Existing investigations on the wound‐healing rate consider only one or two pathogenic factors, and therefore, despite the extensive research on these pathological microenvironments, there is an urgent need to optimize the wound‐healing rate in patients with diabetic foot ulcers. To this end, a multitasking asynchronous collaborative nanosystem is designed in this study. The designed nanosystem can efficiently clear biofilm infections using optimized photodynamic therapy based on a poly photosensitizer ionic liquid (i.e., Ce6IL), reduce local blood glucose concentration using glucose oxidase, and reconstruct blood vessels by stimulating endothelial cell proliferation and migration using nitric oxide. The experimental results indicate that the three‐step sequential collaboration strategy for clearing biofilm infections, reducing glucose concentrations, and reconstructing damaged blood vessels can help significantly accelerate wound healing rate in patients with diabetic foot ulcers.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Wound Healing and Treatments · Diabetic Foot Ulcer Assessment and Management · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopedics Second Affiliated Hospital Air Force Medical University 1 Xinsi Rd Xi'an Shaanxi 710038 China
Department of pharmacy Air Force Medical University 169 Changlexi Rd Xi'an Shaanxi 710032 China
Department of Ultrasonography, First Affiliated Hospital Air Force Medical University 169 Changlexi Rd Xi'an Shaanxi 710032 China
Funding
National Natural Science Foundation of China
References (45)
Show source-provided references
1. 10.1001/jama.2023.1057810.1001/jama.2023.10578 ↗
2. 10.1016/j.jvs.2013.08.00310.1016/j.jvs.2013.08.003 ↗
3. 10.1002/adfm.20210092410.1002/adfm.202100924 ↗
4. 10.1046/j.1464-5491.2001.00460.x10.1046/j.1464-5491.2001.00460.x ↗
5. 10.1002/EXP.2022017310.1002/EXP.20220173 ↗
6. 10.1016/j.ijbiomac.2023.12563610.1016/j.ijbiomac.2023.125636 ↗
7. 10.1002/smll.20220622010.1002/smll.202206220 ↗
8. 10.1021/acsami.3c1606110.1021/acsami.3c16061 ↗
9. 10.1002/advs.20230959010.1002/advs.202309590 ↗
10. 10.1016/j.jconrel.2021.03.03210.1016/j.jconrel.2021.03.032 ↗
11. 10.1021/acsnano.8b0341710.1021/acsnano.8b03417 ↗
12. 10.1016/j.actbio.2021.11.04310.1016/j.actbio.2021.11.043 ↗
13. 10.1126/sciadv.aay541310.1126/sciadv.aay5413 ↗
14. 10.1002/advs.20230325910.1002/advs.202303259 ↗
15. 10.7150/thno.4292210.7150/thno.42922 ↗
16. 10.1021/acsami.2c0358310.1021/acsami.2c03583 ↗
17. 10.1002/EXP.2021008310.1002/EXP.20210083 ↗
18. 10.1038/s41427-022-00444-x10.1038/s41427-022-00444-x ↗
19. 10.1016/j.ijbiomac.2021.07.07810.1016/j.ijbiomac.2021.07.078 ↗
20. 10.1016/j.idc.2007.07.00310.1016/j.idc.2007.07.003 ↗
21. 10.1016/j.dsx.2023.10278310.1016/j.dsx.2023.102783 ↗
22. 10.1016/j.dsx.2013.02.00610.1016/j.dsx.2013.02.006 ↗
23. 10.1021/acs.accounts.0c0086410.1021/acs.accounts.0c00864 ↗
24. 10.2147/IDR.S39372410.2147/IDR.S393724 ↗
25. 10.1021/acsnano.6b0137010.1021/acsnano.6b01370 ↗
26. 10.1016/j.ejphar.2023.17589610.1016/j.ejphar.2023.175896 ↗
27. 10.1007/s00125-017-4331-210.1007/s00125-017-4331-2 ↗
28. 10.1016/j.biopha.2020.11066210.1016/j.biopha.2020.110662 ↗
29. 10.1186/s12989-022-00462-110.1186/s12989-022-00462-1 ↗
30. 10.1002/advs.20220330810.1002/advs.202203308 ↗
31. 10.1016/0142-9612(86)90080-310.1016/0142-9612(86)90080-3 ↗
32. 10.1007/s10456-019-09679-910.1007/s10456-019-09679-9 ↗
33. 10.1038/s41598-022-26831-610.1038/s41598-022-26831-6 ↗
34. 10.1186/1475-2840-9-3110.1186/1475-2840-9-31 ↗
35. 10.1073/pnas.220263111910.1073/pnas.2202631119 ↗
36. 10.1021/acs.biomac.6b0039810.1021/acs.biomac.6b00398 ↗
37. 10.1021/acsami.3c1109310.1021/acsami.3c11093 ↗
38. 10.1016/j.carbpol.2023.12078710.1016/j.carbpol.2023.120787 ↗
39. 10.1016/j.jss.2008.04.02310.1016/j.jss.2008.04.023 ↗
40. 10.1007/BF0153438310.1007/BF01534383 ↗
41. 10.1096/fj.00-0073com10.1096/fj.00-0073com ↗
42. 10.4049/jimmunol.161.10.563310.4049/jimmunol.161.10.5633 ↗
43. 10.1016/j.jbc.2021.10090410.1016/j.jbc.2021.100904 ↗
44. Yamagishi S. · Int. J. Clin. Pharmacol. Res. · 2003 · 23 · 129
45. 10.3390/mi1312209110.3390/mi13122091 ↗